Turnstone Biologics
TSBX
TSBX was delisted on the 8th of August, 2025.
23 hedge funds and large institutions have $4.26M invested in Turnstone Biologics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.04% less ownership
Funds ownership: 47.97% → 44.93% (-3%)
18% less funds holding
Funds holding: 28 → 23 (-5)
23% less capital invested
Capital invested by funds: $5.51M → $4.26M (-$1.25M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$470K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$10.2K |
| 3 |
NA
Nordwand Advisors
Radnor,
Pennsylvania
|
+$8.51K |
| 4 |
Renaissance Technologies
New York
|
+$6.94K |
| 5 |
HF
HRT Financial
New York
|
+$5.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$342K |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$257K |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$95.4K |
| 4 |
Barclays
London,
United Kingdom
|
-$56.7K |
| 5 |
Citigroup
New York
|
-$30.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Fidelity International
Hamilton,
Bermuda
| – | -$95.4K | -192,657 | Closed |
|
|
27
Barclays
London,
United Kingdom
| – | -$56.7K | -114,058 | Closed |
|
|
28
Citigroup
New York
| – | -$30.4K | -61,413 | Closed |
|
29
Goldman Sachs
New York
| – | -$10.2K | -20,518 | Closed |
|
|
VF
30
Virtu Financial
New York
| – | -$7K | -14,810 | Closed |
|
31
Morgan Stanley
New York
| – | -$2.34K | -4,701 | Closed |
|
TSBX Hedge Fund Activity: Q1 2025 in Review
23 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Turnstone Biologics (TSBX) for Q1 2025, worth a combined $4.26M — down 23% from $5.51M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TSBX and 3 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 3 added.
The largest buyer was BML Capital Management, opening a new position worth an estimated $470K. The largest seller was Citadel Advisors, exiting entirely with an estimated $342K sold.
- 23 institutional investors held Turnstone Biologics (TSBX) as of Q1 2025, down from 28 in Q4 2024.
- Funds reported $4.26M of Turnstone Biologics stock for Q1 2025, down 23% quarter-over-quarter.
- 3 funds opened new Turnstone Biologics positions in Q1 2025 and 8 closed out, a net change of -5 holders.
- The largest Turnstone Biologics buyer in Q1 2025 was BML Capital Management, an estimated $470K added.
- The largest Turnstone Biologics seller in Q1 2025 was Citadel Advisors, an estimated $342K sold.
Based on aggregated 13F filings for Q1 2025.